Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AOC-1020
AOC 1020 · 2 trials · 27 indications
Ratio to Baseline
| Arm | Type | Description |
|---|---|---|
| AOC 1020 Regimen | EXPERIMENTAL | AOC 1020 Dose Regimen; Thirty-two doses administered intravenously over 46 months. All participants will receive AOC 1020 at a dose level of 2mg/kg. |
| AOC 1020 Regimen 1 | EXPERIMENTAL | Cohort A: AOC 1020 Dose Regimen 1; Five doses administered intravenously over 9 months |
| AOC 1020 Regimen 2 | EXPERIMENTAL | Cohort B1: AOC 1020 Dose Regimen 2; Five doses administered intravenously over 9 months |
| AOC 1020 Regimen 3 | EXPERIMENTAL | Cohort C: AOC 1020 Dose Regimen 3; Eight doses administered intravenously over approximately 10 months |
| Placebo (Saline) Regimen 1 | PLACEBO_COMPARATOR | Cohort A \& B: Placebo; Five doses administered intravenously over 9 months |
| Placebo (Saline) Regimen 2 | PLACEBO_COMPARATOR | Cohort C: Placebo; Eight doses administered intravenously over approximately 10 months |
| Name | Type | Description |
|---|---|---|
| AOC 1020 | DRUG | AOC 1020 will be administered via intravenous (IV) infusion |
| Placebo | DRUG | Placebo will be administered via intravenous (IV) infusion |
Inclusion Criteria: 1. Ability to provide written informed consent (signed and dated) and any authorizations required by local law and be willing and able to comply with all study requirements. When enrolling participants who are minors, it is necessary to also obtain consent from a legally designa...
AOC 1020 is an investigational small molecule being developed for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD), a neurological condition. It is currently in Phase 2 clinical development and has received Fast Track and Orphan Drug designations from the FDA.
AOC 1020 is being developed by Atrium Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol RNA.
AOC 1020 is currently in Phase 2 clinical development. It has completed a Phase 1/2 study and is being evaluated in an ongoing Phase 2 open-label extension study for FSHD. It is not yet approved by the FDA.
AOC 1020 has been studied in clinical trials including NCT05747924, a completed Phase 1/2 study in participants with FSHD, and NCT06547216, an active Phase 2 open-label extension study. These trials have enrolled participants in the United States, Canada, and the United Kingdom.
Yes, AOC 1020 is also referred to as Del-brax. A Phase 3 clinical trial (NCT07038200) is currently recruiting participants to evaluate Del-brax, also known as AOC 1020, in individuals with FSHD.